| BAF complex vulnerabilities in cancer demonstrated via structure-based PROTAC design W Farnaby, M Koegl, MJ Roy, C Whitworth, E Diers, N Trainor, D Zollman, ... Nature chemical biology 15 (7), 672-680, 2019 | 422 | 2019 |
| SPR-measured dissociation kinetics of PROTAC ternary complexes influence target degradation rate MJ Roy, S Winkler, SJ Hughes, C Whitworth, M Galant, W Farnaby, ... ACS chemical biology 14 (3), 361-368, 2019 | 259 | 2019 |
| A selective and orally bioavailable VHL-recruiting PROTAC achieves SMARCA2 degradation in vivo C Kofink, N Trainor, B Mair, S Wöhrle, M Wurm, N Mischerikow, MJ Roy, ... Nature Communications 13 (1), 5969, 2022 | 99 | 2022 |
| Synthesis of (−)-(S,S)-clemastine by Invertive N → C Aryl Migration in a Lithiated Carbamate AM Fournier, RA Brown, W Farnaby, H Miyatake-Ondozabal, J Clayden Organic Letters 12 (10), 2222-2225, 2010 | 83 | 2010 |
| N to C aryl migration in lithiated carbamates: α-arylation of benzylic alcohols J Clayden, W Farnaby, DM Grainger, U Hennecke, M Mancinelli, ... Journal of the American Chemical Society 131 (10), 3410-3411, 2009 | 71 | 2009 |
| Soticlestat, a novel cholesterol 24-hydroxylase inhibitor shows a therapeutic potential for neural hyperexcitation in mice T Nishi, S Kondo, M Miyamoto, S Watanabe, S Hasegawa, S Kondo, ... Scientific Reports 10 (1), 17081, 2020 | 58 | 2020 |
| Assessing molecular scaffolds for CNS drug discovery J Mayol-Llinas, A Nelson, W Farnaby, A Ayscough Drug Discovery Today 22 (7), 965-969, 2017 | 45 | 2017 |
| Transforming targeted cancer therapy with PROTACs: A forward-looking perspective W Farnaby, M Koegl, DB McConnell, A Ciulli Current opinion in pharmacology 57, 175-183, 2021 | 43 | 2021 |
| Discovery of soticlestat, a potent and selective inhibitor for cholesterol 24-hydroxylase (CH24H) T Koike, M Yoshikawa, HK Ando, W Farnaby, T Nishi, E Watanabe, ... Journal of Medicinal Chemistry 64 (16), 12228-12244, 2021 | 31 | 2021 |
| A facile synthesis of ligands for the von Hippel–Lindau E3 ligase C Steinebach, SA Voell, LP Vu, A Bricelj, I Sosič, G Schnakenburg, ... Synthesis 52 (17), 2521-2527, 2020 | 24 | 2020 |
| Assessment of the Target Engagement and d-Serine Biomarker Profiles of the d-Amino Acid Oxidase Inhibitors Sodium Benzoate and PGM030756 E Howley, M Bestwick, R Fradley, H Harrison, M Leveridge, K Okada, ... Neurochemical Research 42, 3279-3288, 2017 | 21 | 2017 |
| Modular synthesis of thirty lead-like scaffolds suitable for CNS drug discovery J Mayol-Llinàs, W Farnaby, A Nelson Chemical Communications 53 (91), 12345-12348, 2017 | 20 | 2017 |
| Heterocyclic compounds T Koike, M Yoshikawa, H Ando, WJ FARNABY US Patent 8,648,079, 2014 | 19 | 2014 |
| 1-arylcarbonyl-4-oxy-piperidine compounds useful for the treatment of neurodegenerative diseases T Koike, M Yoshikawa, H Ando, WJ Farnaby US Patent 9,193,709, 2015 | 14 | 2015 |
| Heterocyclic compounds T Koike, M Yoshikawa, H Ando, WJ FARNABY US Patent 8,871,766, 2014 | 14 | 2014 |
| Heterocyclic compounds T Koike, M Yoshikawa, H Ando, WJ FARNABY US Patent 8,865,717, 2014 | 14 | 2014 |
| Publisher Correction: BAF complex vulnerabilities in cancer demonstrated via structure-based PROTAC design W Farnaby, M Koegl, MJ Roy, C Whitworth, E Diers, N Trainor, D Zollman, ... Nature Chemical Biology 15 (8), 846-846, 2019 | 13 | 2019 |
| Protein degradation for drug discovery A Ciulli, W Farnaby Drug Discov. Today Technol 31, 1-3, 2019 | 13 | 2019 |
| Novel compounds W Farnaby, C Fieldhouse, K Catrina, N Kinsella, D Livermore, K Merchant, ... US Patent App. 13/591,859, 2013 | 13 | 2013 |
| Heterocyclic compound T Koike, M Yoshikawa, H Ando, WJ Farnaby, S Ikeda, Y Kajita, T Nishi US Patent 9,598,398, 2017 | 11 | 2017 |
